Bio-Techne Corporation (TECH)
- Previous Close
49.78 - Open
50.00 - Bid 46.66 x 200
- Ask 54.02 x 200
- Day's Range
49.78 - 50.77 - 52 Week Range
46.01 - 85.57 - Volume
2,148,317 - Avg. Volume
2,094,614 - Market Cap (intraday)
7.954B - Beta (5Y Monthly) --
- PE Ratio (TTM)
60.62 - EPS (TTM)
0.83 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield 0.32 (0.64%)
- Ex-Dividend Date May 19, 2025
- 1y Target Est
70.11
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
www.bio-techne.comRecent News: TECH
View More
Performance Overview: TECH
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TECH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TECH
View MoreValuation Measures
Market Cap
7.87B
Enterprise Value
8.15B
Trailing P/E
59.98
Forward P/E
22.22
PEG Ratio (5yr expected)
1.05
Price/Sales (ttm)
6.62
Price/Book (mrq)
3.90
Enterprise Value/Revenue
6.74
Enterprise Value/EBITDA
29.00
Financial Highlights
Profitability and Income Statement
Profit Margin
10.89%
Return on Assets (ttm)
4.90%
Return on Equity (ttm)
6.53%
Revenue (ttm)
1.21B
Net Income Avi to Common (ttm)
131.63M
Diluted EPS (ttm)
0.83
Balance Sheet and Cash Flow
Total Cash (mrq)
140.67M
Total Debt/Equity (mrq)
20.99%
Levered Free Cash Flow (ttm)
225.92M
Research Analysis: TECH
View MoreResearch Reports: TECH
View MoreBio-Techne Earnings: Strong Growth in Protein Sciences, but US Academic Market Uncertain
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
RatingPrice TargetLife Science Industry: Tariffs Remain Concerning, but No Major Change to Our Views Currently
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
RatingPrice TargetBio-Techne Earnings: Strong Results on Recovering Biopharma Demand; Shares Modestly Undervalued
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
RatingPrice TargetStronger end markets drive 2Q25 results
Based in Minneapolis, Bio-Techne develops and markets protein-based instruments and reagents for research and clinical use. Its customers include companies in the pharmaceutical and biotech industries, as well as academic research institutions. The company's products and solutions aid in drug discovery and provide the means for accurate clinical tests and diagnoses. Through its Protein Sciences business segment, Bio-Techne is one of the world's leading suppliers of proteins, such as cytokines and growth factors, immunoassays, antibodies, and reagents to the biotech and academic research communities. The Diagnostics and Spatial Biology segment provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays, and other bulk and custom reagents for the in-vitro diagnostic market.
RatingPrice Target